SG/CALL/MEDTRONIC/105/0.1/21.06.24 Stock

Warrant

DE000SV44AA1

Delayed Deutsche Boerse AG 05:01:03 2024-05-29 am EDT
0.001 EUR 0.00% Intraday chart for SG/CALL/MEDTRONIC/105/0.1/21.06.24
6 months-96.15%
Current year-97.22%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-29 0.001 0.00%
24-05-28 0.001 0.00%
24-05-27 0.001 0.00%
24-05-24 0.001 0.00%
24-05-23 0.001 0.00%

Delayed Quote Deutsche Boerse AG

Last update May 29, 2024 at 05:01 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying MEDTRONIC PLC
IssuerLogo Issuer Société Générale Société Générale
WKN SV44AA
ISINDE000SV44AA1
Date issued 2023-05-08
Strike 105 $
Maturity 2024-06-21 (24 Days)
Parity 10 : 1
Emission price 0.46
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.48
Lowest since issue 0.001
Spread 0.019
Spread %95.00%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
82 USD
Average target price
94.77 USD
Spread / Average Target
+15.58%
Consensus